(5-溴-吡嗪-2-基)-(1,2,3,4-四氢-萘-2-基甲基)-胺 | 1040527-09-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: (5-溴-吡嗪-2-基)-(1,2,3,4-四氢-萘-2-基甲基)-胺
• 英文名称: (5-bromo-pyrazin-2-yl)-(1,2,3,4-tetrahydro-naphthalen-2-ylmethyl)-amine
• CAS: 1040527-09-0
• 化学式: C₁₅H₁₆BrN₃
• 分子量: 318.216
• InChiKey: JUGNVHXKZYWXTC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.46
• 重原子数：
  19.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  37.81
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  (5-溴-吡嗪-2-基)-(1,2,3,4-四氢-萘-2-基甲基)-胺 、 4-硼-L-苯丙氨酸 在 bis-triphenylphosphine-palladium(II) chloride 、 sodium carbonate 作用下， 以 水 、 乙腈 为溶剂， 反应 0.1h， 生成 (2S)-2-amino-3-(4-(5-((1,2,3,4-tetrahydronaphthalen-2-yl)methylamino)pyrazin-2-yl)phenyl)propanoic acid
  参考文献：
  名称：

  Modulation of Peripheral Serotonin Levels by Novel Tryptophan Hydroxylase Inhibitors for the Potential Treatment of Functional Gastrointestinal Disorders

  摘要：

  The discovery of a novel class of peripheral tryptophan hydroxylase (TPH) inhibitors is described. This class of TPH inhibitors exhibits excellent potency in in vitro biochemical and cell-based assays, and it selectively reduces serotonin levels in the murine intestine after oral administration without affecting levels in the brain. These TPH1 inhibitors may provide novel treatments for gastrointestinal disorders associated with dysregulation of the serotonergic system, such as chemotherapy-induced emesis and irritable bowel syndrome.

  DOI：

  10.1021/jm800338j
• 作为产物：
  描述：

  2-氨基-5-溴吡嗪 、 1,2,3,4-四氢萘-2-甲醛 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以0.33 g的产率得到(5-溴-吡嗪-2-基)-(1,2,3,4-四氢-萘-2-基甲基)-胺
  参考文献：
  名称：

  Modulation of Peripheral Serotonin Levels by Novel Tryptophan Hydroxylase Inhibitors for the Potential Treatment of Functional Gastrointestinal Disorders

  摘要：

  The discovery of a novel class of peripheral tryptophan hydroxylase (TPH) inhibitors is described. This class of TPH inhibitors exhibits excellent potency in in vitro biochemical and cell-based assays, and it selectively reduces serotonin levels in the murine intestine after oral administration without affecting levels in the brain. These TPH1 inhibitors may provide novel treatments for gastrointestinal disorders associated with dysregulation of the serotonergic system, such as chemotherapy-induced emesis and irritable bowel syndrome.

  DOI：

  10.1021/jm800338j